National Health (Immunisation Program — Designated Vaccines) Determination 2009 (No.3)[1]

National Health Act 1953

I, MARY MURNANE, Delegate of the Minister for Health and Ageing, make this Determination under subsections 9B (2) and (5) of the *National Health Act 1953*.

Dated twenty third ## December 2009

Mary Murnane
Deputy Secretary
Department of Health and Ageing
Delegate of the Minister for Health and Ageing

Contents

1 Name of Determination

This Determination is the *National Health (Immunisation Program — Designated Vaccines) Determination 2009 (No.3)*.

2 Commencement

This Determination commences on the day after it is registered.

3 Revocation

The *National Health (Immunisation Program — Designated Vaccines) Determination 2009 (No. 2)* is revoked.

4 Definitions

µg means microgram.

Act means the *National Health Act 1953*.

$CCID_{50}$ means cell culture infectious dose 50%, being the quantity of an infectious agent that when inoculated onto a number of susceptible cell cultures will infect 50% of the individual cultures.

FHA means filamentous haemagglutinin.

FIM 2+3 means fimbrial agglutinogens 2+3.

IU means International Unit.

member of a medical risk group means a person mentioned in any of the following paragraphs:

(a) a person who has congenital immune deficiency (including symptomatic IgG subclass or isolated IgA deficiency) other than a person who requires monthly immunoglobulin infusion;

(b) a person who has sufficient immune reconstitution for a vaccine response to be expected and is receiving a course of:

  (i) immunosuppressive therapy, including corticosteroid therapy equivalent to greater than 2mg/kg per day of prednisone for more than 2 weeks; or

  (ii) radiation therapy;

(c) a person who has compromised splenic function because of:

  (i) sickle haemoglobinopathies; or

  (ii) congenital or acquired functional or anatomical asplenia;

Federal Register of Legislative Instruments F2010L00017

(d) a person who has an HIV infection, either before or after the development of AIDS;

(e) a person who has:

(i) renal failure; or

(ii) relapsing or persistent nephrotic syndrome;

(f) a person who has Down's syndrome;

(g) a person who has heart disease associated with cyanosis or cardiac failure;

(h) a person who was a premature infant and who has, or has had, chronic lung disease;

(i) a person who was born at less than 28 weeks gestation;

(j) a person who has cystic fibrosis;

(k) a person who has insulin-dependent diabetes mellitus;

(l) a person who has proven or presumptive cerebrospinal fluid leak;

(m) a person who has an intracranial shunt;

(n) a person who has a cochlear implant.

PFU means plaque forming units.

PRN means pertactin.

PT means pertussis toxoid.

$TCID_{50}$ means tissue culture infectious dose 50%, being the quantity of an infectious agent that when inoculated onto a number of susceptible tissue cultures will infect 50% of the individual cultures.

5 Designated vaccines

For subsection 9B (2) of the Act, a vaccine mentioned in column 2 of Schedule 1 is a designated vaccine.

6 Circumstances in which designated vaccines may be provided

For subsection 9B (5) of the Act, a designated vaccine may be provided in the circumstances mentioned for it in Schedule 1.

7 Circumstances in which designated vaccines may be provided — particular vaccines

(1) For items 109 and 110 of Schedule 1, a designated vaccine mentioned in that item may be provided in the following circumstances:

(a) a first dose of the vaccine may be provided to a person:

(i) who is not an Aboriginal or a Torres Strait Islander; and

(ii) who is at least 65 years;

(b) a first dose of the vaccine may be provided to a person:

(i) who is an Aboriginal or a Torres Strait Islander; and

(ii) who is at least 15 years but less than 50 years; and

(iii) who:

(A) has heart disease; or

(B) has kidney disease; or

(C) has lung disease; or

(D) has asthma; or

(E) has diabetes; or

(F) has an immune compromising condition; or

(G) in the opinion of a medical practitioner, consumes alcohol excessively; or

(H) smokes tobacco;

(c) a first dose of the vaccine may be provided to a person:

(i) who is an Aboriginal or a Torres Strait Islander; and

(ii) who is at least 50 years; and

(iii) who has not received a dose of the vaccine under paragraph (b);

(d) a second dose of the vaccine may be provided to a person mentioned in paragraph (a), (b) or (c) 5 years after the first dose was provided to the person under paragraph (a), (b) or (c);

(e) a third dose of the vaccine may be provided to a person mentioned in paragraph (b) after the later of the following:

(i) the end of 5 years after the second dose was provided to the person under paragraph (d);

(ii) the person turns 50;

(f) a dose of the vaccine may be provided to a child:

(i) who is an Aboriginal or a Torres Strait Islander; and

(ii) who is at least 18 months but not more than 24 months; and

(iii) who lives in Queensland, Western Australia, South Australia or the Northern Territory;

(g) a dose of the vaccine may be provided to a child:

(i) who is at least 4 years but less than 6 years; and

(ii) who is a member of a medical risk group.

(2) For item 111 of Schedule 1, a designated vaccine mentioned in that item may be provided to a person:

(a) who is at least 15 years; and

(b) who is one of the following:

(i) an abattoir worker;

(ii) a sheep shearer;

(iii) a sheep, dairy or beef cattle farmer;

(iv) an employee of a sheep, dairy or beef cattle farmer;

(v) a member of the family of a sheep, dairy or beef cattle farmer who works on the sheep, dairy or beef cattle farm;

(vi) an employee of a tannery; and

Federal Register of Legislative Instruments F2010L00017

(c) who has had a Q-Vax skin test and has received a negative result for that test; and

(d) who has had a *Coxiella burnetii* antibody serum study and has received a negative result for that study.

(3) For item 203 of Schedule 1, a designated vaccine mentioned in that item may be provided in the following circumstances:

(a) a dose of the vaccine may be provided to a newborn infant as soon as practicable after birth but no later than 7 days after birth;

(b) a first dose of the vaccine may be provided to a child who is at least 10 years but less than 14 years;

(c) a second dose of the vaccine may be provided to a child mentioned in paragraph (b) 1 month after the first dose was provided to the child under paragraph (b);

(d) a third dose of the vaccine may be provided to a child mentioned in paragraph (b) 5 months after the second dose was provided to the child under paragraph (c).

(4) For items 205 and 206 of Schedule 1, a designated vaccine mentioned in those items may be provided to:

(a) a person who is at least 65 years; or

(b) an Aboriginal and Torres Strait Islander person who is at least 15 years; or

(c) a person who is at least 6 months

(i) who:

(A) has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or

(B) has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or

(C) has another chronic illness requiring regular medical follow-up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug-induced immune impairment); or

(D) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or

(E) has impaired immunity, including HIV infection; or

(F) is aged 6 months to 10 years and is receiving long-term aspirin therapy; or

(G) is pregnant.

Schedule 1 Designated vaccines and circumstances in which vaccines may be provided

(sections 5 and 6)

Part 1 Bacterial vaccines

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
101	**Vaccine** Diphtheria, tetanus and pertussis (adult/adolescent) **Circumstances** Vaccine may be provided to a child who is at least 10 years but less than 18 years	Boostrix	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid — not less than 2 IU; (b) tetanus toxoid — not less than 20 IU; (c) PT — 8 µg; (d) FHA — 8 µg; (e) PRN — 2.5 µg	1 dose (booster)
102	**Vaccine** Diphtheria, tetanus and pertussis (adult/adolescent) **Circumstances** Vaccine may be provided to a child who is at least 10 years but less than 18 years	Adacel	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid — not less than 2 IU; (b) tetanus toxoid — not less than 20 IU; (c) PT — 2.5 µg; (d) FHA — 5 µg; (e) PRN — 3 µg (f) FIM 2+3 — 5 µg	1 dose (booster)

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
103	**Vaccine** *Haemophilus influenzae* type b (Hib) (monovalent PRP-T) **Circumstances** Vaccine may be provided to a child who is about 12 months	ActHib or Hiberix	Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent	Purified Hib capsular polysaccharide conjugated to tetanus toxoid — 10 μg	1 dose (booster)
104	**Vaccine** *Haemophilus influenzae* type b (Hib) (monovalent PRP-OMP) **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 12 months	Pedvax	Vial for injection (0.5mL)	Purified Hib capsular polysaccharide conjugated to meningococcal protein — 7.5 μg	3 doses
105	**Vaccine** Meningococcal C (conjugate) **Circumstances** Vaccine may be provided: (a) to a child who is about 12 months; or (b) in the period commencing on 1 January 2006 and ending at the end of 30 June 2007, to a person: (i) who, on 1 January 2003, was at least 1 year but less than 20 years; and (ii) who has not received a vaccine mentioned in this item or item 106 or 107	Meningitec	Injection (0.5mL)	Meningococcal group C oligosaccharide conjugated to diphtheria protein — 10 μg	1 dose

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
106	**Vaccine** Meningococcal C (conjugate) **Circumstances** Vaccine may be provided: (a) to a child who is about 12 months; or (b) in the period commencing on 1 January 2006 and ending at the end of 30 June 2007, to a person: (i) who, on 1 January 2003, was at least 1 year but less than 20 years; and (ii) who has not received a vaccine mentioned in this item or item 105 or 107	Menjugate	Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent	Meningococcal group C oligosaccharide conjugated to diphtheria protein — 10 µg	1 dose
107	**Vaccine** Meningococcal C (conjugate) **Circumstances** Vaccine may be provided: (a) to a child who is about 12 months; or (b) in the period commencing on 1 January 2006 and ending at the end of 30 June 2007, to a person: (i) who, on 1 January 2003, was at least 1 year but less than 20 years; and (ii) who has not received a vaccine mentioned in this item or item 105 or 106	NeisVac-C	Injection (0.5mL)	Meningococcal group C oligosaccharide conjugated to tetanus toxoid protein — 10 µg	1 dose

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
108	**Vaccine** Pneumococcal (conjugate, 7-valent) **Circumstances** Vaccine may be provided to: (a) a child who is about 2, 4 or 6 months; or (b) a child who is about 12 months and is a member of a medical risk group	Prevenar	Injection (0.5mL)	Polysaccharides of *Streptococcus pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to diphtheria protein — 2 µg of each of serotypes 4, 9V, 14, 18C, 19F and 23F, and 4 µg of serotype 6B	3 or 4 doses
109	**Vaccine** Pneumococcal (conjugate, 10-valent) **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months, or 18 months	Synflorix	Injection (0.5mL)	Polysaccharides of Streptococcus *pneumoniae* serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F conjugated to protein D (a surface protein from non-typeable *Haemophilus influenzae*), serotype 18C conjugated to tetanus toxoid protein and serotype 19F conjugated to diptheria toxoid protein – 1 µg of each 1, 4, 6B, 7F, 9V, 14 and 23F and 3 µg of 4, 18C and 19F.	4 dose

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
110	**Vaccine** Pneumococcal (polysaccharide, 23-valent) **Circumstances** Vaccine may be provided in the circumstances set out in subsection 7 (1)	PneumoVax 23	Injection (0.5mL)	Polysaccharides of *Streptococcus pneumoniae* serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F — 25 µg of each serotype	1 to 3 doses
111	**Vaccine** Q fever **Circumstances** Vaccine may be provided in the circumstances set out in subsection 7 (2)	Q-Vax	Injection (0.5mL)	Killed *Coxiella burnetii* — 25 µg	1 dose

Part 2 Viral vaccines

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
201	**Vaccine** Hepatitis A (monovalent) **Circumstances** Vaccine may be provided to a child: (a) who is an Aboriginal or a Torres Strait Islander; and (b) who is at least 1 year but less than 5 years; and (c) who lives in Queensland, Western Australia, South Australia or the Northern Territory	VAQTA Paediatric/ Adolescent	Injection (0.5mL)	Hepatitis A virus protein — 25 units of the hepatitis A virus protein	2 doses, with the second dose given 6 months after the first dose
202	**Vaccine** Hepatitis B (monovalent adult) **Circumstances** Vaccine may be provided to a child who is at least 10 years but less than 14 years	H-B-Vax II	Vial for injection (1mL)	Hepatitis B surface antigen protein — 10 µg	2 doses, with the second dose given 4 to 6 months after the first dose
203	**Vaccine** Hepatitis B (monovalent paediatric) **Circumstances** Vaccine may be provided in the circumstances set out in subsection 7 (3)	Engerix-B	Vial for injection (0.5mL)	Hepatitis B surface antigen protein — 10 µg	1 dose or 3 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
204	**Vaccine** Hepatitis B (monovalent paediatric) **Circumstances** Vaccine may be provided to a newborn infant as soon as practicable after birth but no later than 7 days after birth	H-B-Vax II	Vial for injection (0.5mL)	Hepatitis B surface antigen protein — 5 µg	1 dose

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
205	**Vaccine** Influenza **Circumstances** Vaccine may be provided in the circumstances set out in subsection 7 (4)	Fluvax or Vaxigrip or Influvac	Injection (0.5mL)	Like strains of each of the following: • A (H1N1): an A/California/7/2009 (H1N1) - like strain, 15 µg HA per dose • A (H3N2): an A/Perth/16/2009 (H3N2) - like strain, 15 µg HA per dose • B: a B/Brisbane/60/2008 - like strain, 15 µg HA per dose The following viruses are recommended as suitable vaccine strains: • A/California/7/2009 (H1N1) (NYMC X-179A, NYMC X-181, NYMC X-181A, NIBRG-121, NIBRG-121xp) • A/Perth/16/2009 (H3N2)- like virus (NYMC X-183) • B/Brisbane/60/2008	For children older than 6 months but less than 9 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that. For persons 9 years and above, 1 dose per calendar year Note – For children aged between 6 months and less than 3 years the dose is 0.25ml

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
206	**Vaccine** Influenza **Circumstances** Vaccine may be provided in the circumstances set out in subsection 7 (4)	Fluvax Junior or Vaxigrip Junior	Injection (0.25mL)	Like strains of each of the following: • A (H1N1): an A/California/7/2009 (H1N1) - like strain, 7.5 µg HA per dose • A (H3N2): an A/Perth/16/2009 (H3N2) - like strain, 7.5 µg HA per dose • B: a B/Brisbane/60/2008 - like strain, 7.5 µg HA per dose The following viruses are recommended as suitable vaccine strains: • A/California/7/2009 (H1N1) (NYMC X-179A, NYMC X-181, NYMC X-181A, NIBRG-121, NIBRG-121xp) • A/Perth/16/2009 (H3N2)- like virus (NYMC X-183) • B/Brisbane/60/2008	For children older than 6 months but less than 3 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
207	**Vaccine** Measles, mumps and rubella **Circumstances** Vaccine may be provided to a child who is about 12 months or 4 years	M-M-R II	Refrigerated lyophilised preparation for injection (0.5mL)	Each of the following live attenuated viruses: (a) measles virus (Edmonston strain) — 1000 TCID50; (b) mumps virus (Jeryl Lynn strain) — 5000 TCID50; (c) rubella virus (Wistar RA 27/3 strain) — 1000 TCID50	2 doses
208	**Vaccine** Measles, mumps and rubella **Circumstances** Vaccine may be provided to a child who is about 12 months or 4 years	Priorix	Refrigerated lyophilised preparation for injection (0.5mL)	Each of the following live attenuated viruses: (a) measles virus (Schwarz strain) — $10^{3.0}$ $CCID_{50}$; (b) mumps virus (RIT 4385 derived from the Jeryl Lynn strain) — $10^{3.7}$ $CCID_{50}$; (c) rubella virus (Wistar RA 27/3 strain) — $10^{3.0}$ $CCID_{50}$	2 doses
209	**Vaccine** Poliomyelitis **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months or 4 years, if all other vaccines containing poliovirus are unsuitable	IPOL	Injection (0.5mL)	Each of the following killed whole polioviruses: (a) type 1 (Mahoney) — 40 D-antigen units; (b) type 2 (MEF-1) — 8 D-antigen units; (c) type 3 (Saukett) — 32 D-antigen units	No more than 4 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
210	**Vaccine** Varicella **Circumstances** Vaccine may be provided to: (a) a child who is about 18 months; or (b) a child who is at least 10 years but less than 14 years, if the child: (i) has not had varicella; and (ii) has not been vaccinated against varicella	Varilrix	Refrigerated lyophilised preparation for injection (0.5mL)	Live attenuated Oka strain of the varicella-zoster virus — $10^{3.3}$ PFU	1 dose
211	**Vaccine** Varicella **Circumstances** Vaccine may be provided to: (a) a child who is about 18 months; or (b) a child who is at least 10 years but less than 14 years, if the child: (i) has not had varicella; and (ii) has not been vaccinated against varicella	Varivax Refrigerated	Refrigerated lyophilised preparation for injection (0.5mL)	Live attenuated Oka/Merck strain of the varicella-zoster virus — at least 1350 PFU	1 dose

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
212	**Vaccine** Human papillomavirus (HPV) **Circumstances** Vaccine may be provided to: (a) a female who is at least 12 years but less than 14 years; or (b) a female who, between 1 March 2007 – 30 June 2009, is at least 13 years but less than 27 years and has received at least one before 1 July 2009	Gardasil	Injection (0.5mL)	Each of the following: (a) HPV 6 L1 protein — 20 µg; (b) HPV 11 L1 protein — 40 µg; (c) HPV 16 L1 protein — 40 µg; (d) HPV 18 L1 protein — 20 µg	3 doses
213	**Vaccine** Human papillomavirus (HPV) **Circumstances** Vaccine may be provided to: a female who is at least 12 years but less than 14 years	Cervarix	Injection (0.5mL)	Each of the following: (a) HPV 16 L1 protein - 20µg; (b) HPV 18 L1 protein - 20µg	3 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
214	**Vaccine** Rotavirus **Circumstances** Vaccine may be provided to a child who: (a) is about 2 or 4 months	Rotarix	Oral suspension (1.5mL) in oral applicator	Human rotavirus vaccine, live attenuated, RIX 4414 strain (G1P[8]) — not less than 10^6 $CCID_{50}$	2 doses: (a) first dose given at 6 to 14 weeks of age; (b) second dose given at 14 to 24 weeks of age

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
215	**Vaccine** Rotavirus **Circumstances** Vaccine may be provided to a child who: (a) is about 2, 4 or 6 months	RotaTeq	Oral solution (2.0mL)	Live pentavalent reassortant vaccine containing each of the following: (a) G1 — 2.2 x 10^6 IU; (b) G2 — 2.8 x 10^6 IU; (c) G3 — 2.2 x 10^6 IU; (d) G4 — 2.0 x 10^6 IU; (e) P1 (8) — 2.3 x 10^6 IU	3 doses: (a) first dose given at 6 to 14 weeks old; (b) second dose given at 14 to 24 weeks old; (c) third dose given before 32 weeks old

Part 3 Combined bacterial and viral vaccines

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
301	**Vaccine** Diphtheria, tetanus, pertussis and poliomyelitis **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months, or between 3 years and 6 months and 4 years	Infanrix-IPV	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid — not less than 30 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 25 µg; (d) FHA — 25 µg; (e) PRN — 8 µg; (f) inactivated poliovirus type 1 (Mahoney) — 40 D-antigen units; (g) inactivated poliovirus type 2 (MEF-1) — 8 D-antigen units; (h) inactivated poliovirus type 3 (Saukett) —32 D-antigen units	4 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
302	**Vaccine** Diphtheria, tetanus, pertussis and poliomyelitis **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months, or between 3 years and 6 months and 4 years	Quadracel	Vial for injection (0.5mL)	Each of the following: (a) diphtheria toxoid — not less than 30 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 20 µg; (d) FHA — 20 µg; (e) PRN — 3 µg; (f) FIM 2+3 — 5 µg; (g) inactivated poliovirus type 1 (Mahoney) — 40 D-antigen units; (h) inactivated poliovirus type 2 (MEF-1) — 8 D-antigen units; (i) inactivated poliovirus type 3 (Saukett) — 32 D-antigen units	4 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
303	**Vaccine** Diphtheria, tetanus, pertussis, poliomyelitis and hepatitis B **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months	Infanrix-Penta	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid — not less than 30 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 25 µg; (d) FHA — 25 µg; (e) PRN — 8 µg; (f) inactivated poliovirus type 1 (Mahoney) — 40 D-antigen units; (g) inactivated poliovirus type 2 (MEF-1) — 8 D-antigen units; (h) inactivated poliovirus type 3 (Saukett) — 32 D-antigen units; (i) recombinant hepatitis B surface antigen — 10 µg	3 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
304	**Vaccine** Diphtheria, tetanus, pertussis, poliomyelitis and *Haemophilus influenzae* type b (Hib) **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months	Pediacel	Injection (0.5mL)	Each of the following: (a) diphtheria toxoid — not less than 30 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 20 µg; (d) FHA — 20 µg; (e) PRN — 3 µg; (f) FIM 2+3 — 5 µg; (g) inactivated poliovirus type 1 (Mahoney) — 40 D-antigen units; (h) inactivated poliovirus type 2 (MEF-1) — 8 D-antigen units; (i) inactivated poliovirus type 3 (Saukett) — 32 D-antigen units; (j) purified Hib capsular polysaccharide conjugated to tetanus toxoid — 10 µg	3 doses

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
305	**Vaccine** Diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and *Haemophilus influenzae* type b (Hib) **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 6 months	Infanrix-Hexa	Injection (0.5mL) combination pack	Each of the following: (a) diphtheria toxoid — not less than 30 IU; (b) tetanus toxoid — not less than 40 IU; (c) PT — 25 µg; (d) FHA — 25 µg; (e) PRN — 8 µg; (f) inactivated poliovirus type 1 (Mahoney) — 40 D-antigen units; (g) inactivated poliovirus type 2 (MEF-1) — 8 D-antigen units; (h) inactivated poliovirus type 3 (Saukett) — 32 D-antigen units; (i) recombinant hepatitis B surface antigen — 10 µg; (j) purified Hib capsular polysaccharide conjugated to tetanus toxoid — 10 µg	3 doses
306	**Vaccine** Hepatitis B and *Haemophilus influenzae* type b (Hib) **Circumstances** Vaccine may be provided to a child who is about 2, 4 or 12 months	Comvax	Vial for injection (0.5mL)	Each of the following: (a) Hepatitis B surface antigen — 5µg; (b) purified Hib capsular polysaccharide conjugated to meningococcal protein — 7.5µg	3 doses

Note

1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*. See http://www.frli.gov.au.